Short bowel syndrome
Drug research and approvals for short bowel syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 20 studies of short bowel syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 4 approved and 12 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 7
- FDA orphan approvals: 4
- EU medicines: 2
Recruiting Now
Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗- A Clinical Study of FT1 in Patients With Short Bowel SyndromeNCT07704047 · Phase 2 · Chongqing Peg-Bio Biopharm Co., Ltd. · starts Aug 30, 2026
- A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short…NCT07742735 · Phase 3 · VectivBio AG · starts Aug 1, 2026
- AGE Accumulation in Patients on Long-term Parenteral NutritionNCT07392801 · Not applicable · University Hospital, Bordeaux · starts Jul 22, 2026
- Kodo Millet Porridge and Its Effects on Gut Health and Metabolic SyndromeNCT07703371 · Not applicable · JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH · starts Jun 1, 2026
- A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel SyndromeNCT07319832 · Not reported · Takeda · starts Mar 5, 2026
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSNCT07197944 · Phase 3 · Zealand Pharma · starts Feb 11, 2026
- Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive FunctionNCT07713641 · Not applicable · Universitaire Ziekenhuizen KU Leuven · starts Oct 24, 2025
- Resting Energy Expenditure by Gastrointestinal Functional StatusNCT07714499 · Not applicable · Institute of Oncology Ljubljana · starts Oct 1, 2025
- Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without…NCT06904872 · Phase 2 · Napo Therapeutics, S.p.A. · starts May 29, 2025
- Elemental 028 Extra Case StudiesNCT06877923 · Not applicable · Nutricia UK Ltd · starts May 1, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 17, 2026 | A parallel-group treatment, phase 3, double-blind, randomized, 2-arm study to investigate the efficacy and safety of apraglutide compared with placebo in adult…APRAGLUTIDE (TA799, FE 203799) | VECTIVBIO AG | Pending |
| Nov 26, 2025 | A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of glepaglutide in adult patients with…GLEPAGLUTIDE | Zealand Pharma | Ongoing |
| Mar 17, 2022 | A 104-week, multicenter, single-arm, longterm, phase 3 extension trial investigating the safety and efficacy of glepaglutide in adult patients with short bowel…GLEPAGLUTIDE | Zealand Pharma | Closed |
| May 16, 2019 | A double-blind phase 3 extension trial assessing the long term safety and efficacy of glepaglutide in patients with short bowel syndrome (sbs)GLEPAGLUTIDE | Zealand Pharma | Closed |
| Oct 5, 2018 | A phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with…GLEPAGLUTIDE | Zealand Pharma | Closed |
| Sep 30, 2016 | A prospective, open-label, long-term safety and efficacy study of teduglutide in pediatric patientswith short bowel syndrome who completed ted-c14-006REVESTIVE | Takeda Pharmaceuticals USA | Closed |
| May 19, 2016 | A 24-week double-blind, safety, efficacy, and pharmacodynamic study investigating two doses of teduglutide in pediatric subjects through 17 years of age with…REVESTIVE | SHIRE-NPS PHARMACEUTICALS INC. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 16| May 16, 2019 | GATTEXGATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Dec 21, 2012 | GATTEXTreatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Jun 10, 2004 | NutreStoreTreatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human… | Emmaus Medical, Inc. | Approved |
| Dec 1, 2003 | ZorbtiveTreatment of short bowel syndrome in patients receiving specialized nutritional support | EMD Serono, Inc. | Approved |
| Mar 9, 2023 | Arginine butyrateTreatment of Short Bowel Syndrome | Baxter Healthcare Corporation | Designated |
| May 1, 2019 | human glucagon-like peptide-2 analogue linked to a human…Treatment of short bowel syndrome | Hanmi Pharmaceutical Co. Ltd. | Designated |
| Dec 20, 2018 | apraglutideTreatment of short bowel syndrome (SBS) | Ironwood Pharmaceuticals, Inc. | Designated |
| Oct 11, 2018 | Glucagon-Like Peptide 2 fused to hyFcTreatment of short bowel syndrome | Genexine | Designated |
| Oct 20, 2017 | glepaglutideTreatment of short bowel syndrome | Zealand Pharma A/S | Designated |
| Aug 2, 2017 | crofelemerTreatment of short bowel syndrome | Napo Pharmaceuticals, Inc. | Designated |
| Feb 14, 2017 | melatoninTreatment of short bowel syndrome | WORPHMED Srl | Designated |
| Oct 7, 2015 | recombinant fusion protein comprising exenatide and XTENTreatment of short bowel syndrome. | 9 Meters Biopharma, Inc. | Designated |
| Jun 1, 2015 | docosahexaenoic acidTreatment of short bowel syndrome | Micelle BioPharma, Inc. | Designated |
| Apr 6, 2015 | human insulin (rDNA)Treatment of short bowel syndrome (SBS). | ELGAN Pharma Ltd. | Designated |
| Dec 2, 2011 | opium tinctureTreatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment | Valeant Pharmaceuticals International, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jan 8, 2026 | Teduglutide Viatristeduglutide · generic | Viatris Limited | EMA ↗ |
| Aug 30, 2012 | Revestiveteduglutide | Takeda Pharmaceuticals International AG Ireland | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA